Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

Hospital Clinic of Barcelona20 enrolled

Overview

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis. The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Hepatitis C Liver Fibrosis

Interventions

LosartanDRUG

Eligibility

Sex: ALLMin age: 35 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age between 35 and 65 years * chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score). * non-responder or contraindication to antiviral therapy. Exclusion Criteria: * any other cause of liver disease * HIV positive * alcohol consumption * arterial hypertension * creatinine \> 1.5mg/dL * treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months. * antiviral therapy in the past 12 months * contraindications to oral losartan

Outcomes

Primary Outcomes

Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.